Literature DB >> 16138335

Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection.

Motohiko Okano1, Keisei Kawa, Hiroshi Kimura, Akihiro Yachie, Hiroshi Wakiguchi, Akihiko Maeda, Shosuke Imai, Shouichi Ohga, Hirokazu Kanegane, Shigeru Tsuchiya, Tomohiro Morio, Masaaki Mori, Shumpei Yokota, Shinsaku Imashuku.   

Abstract

Since the initial report of unusual manifestations possibly associated with chronic active Epstein-Barr virus (EBV) infection (CAEBV), nearly three decades have passed. During this period, reported cases with this entity have dramatically increased in the world. Additionally, recent development of diagnostic procedures, including molecular biological and immunological techniques, have provided us with the ability to define certain diseases, especially malignant disorders. Guidelines, derived mainly from the current literature and recent experiences with CAEBV in Japan, for diagnosing CAEBV are proposed to clarify this enigmatic disease. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 16138335     DOI: 10.1002/ajh.20398

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  73 in total

1.  Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification.

Authors:  Ichiro Yonese; Chizuko Sakashita; Ken-Ichi Imadome; Tohru Kobayashi; Masahide Yamamoto; Akihisa Sawada; Yoshinori Ito; Noriko Fukuhara; Asao Hirose; Yusuke Takeda; Masanori Makita; Tomoyuki Endo; Shun-Ichi Kimura; Masataka Ishimura; Osamu Miura; Shouichi Ohga; Hiroshi Kimura; Shigeyoshi Fujiwara; Ayako Arai
Journal:  Blood Adv       Date:  2020-07-14

2.  Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.

Authors:  J Ogawa; M Harigai; T Akashi; K Nagasaka; F Suzuki; S Tominaga; N Miyasaka
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

3.  Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis.

Authors:  Ayako Arai; Ken-Ichi Imadome; Yuko Watanabe; Mayumi Yoshimori; Takatoshi Koyama; Takeharu Kawaguchi; Chiaki Nakaseko; Shigeyoshi Fujiwara; Osamu Miura
Journal:  Int J Hematol       Date:  2011-04-14       Impact factor: 2.490

4.  Successful reduced-intensity stem cell transplantation with cord blood for a poor-prognosis adult with refractory chronic active epstein-barr virus infection.

Authors:  Masao Nakagawa; Satoshi Hashino; Mutsumi Takahata; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Sachiko Ando; Masahiro Asaka
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

5.  Evaluation of the Epstein-Barr virus R-gene quantification kit in whole blood with different extraction methods and PCR platforms.

Authors:  Samira Fafi-Kremer; Patrice Morand; Come Barranger; Gérard Barguès; Stéphane Magro; Jérôme Bés; Philippe Bourgeois; Martine Joannes; Jean-Marie Seigneurin
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

6.  [Fulminant EBV meningoencephalitis : Good clinical outcome in a young, immunocompetent female].

Authors:  F Derler; S Seidel; D Bengel
Journal:  Nervenarzt       Date:  2017-10       Impact factor: 1.214

7.  Possible autoimmune hepatitis induced after chronic active Epstein-Barr virus infection.

Authors:  Yoshiko Wada; Chikako Sato; Kyoko Tomita; Rika Ishii-Aso; Hiroaki Haga; Kazuo Okumoto; Yuko Nishise; Hisayoshi Watanabe; Takafumi Saito; Yoshiyuki Ueno
Journal:  Clin J Gastroenterol       Date:  2013-11-23

8.  Cardiovascular complications associated with chronic active Epstein-Barr virus infection.

Authors:  Jun Muneuchi; Shouichi Ohga; Masataka Ishimura; Kazuyuki Ikeda; Kenichiro Yamaguchi; Akihiko Nomura; Hidetoshi Takada; Yasunobu Abe; Toshiro Hara
Journal:  Pediatr Cardiol       Date:  2009-01-30       Impact factor: 1.655

9.  Characterization of variants in the promoter of BZLF1 gene of EBV in nonmalignant EBV-associated diseases in Chinese children.

Authors:  Yingkang Jin; Zhengde Xie; Gen Lu; Shuang Yang; Kunling Shen
Journal:  Virol J       Date:  2010-05-10       Impact factor: 4.099

10.  Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.

Authors:  Ryan Incrocci; Samira Hussain; Amanda Stone; Kathryn Bieging; Lauren A C Alt; Michael J Fay; Michelle Swanson-Mungerson
Journal:  Cell Immunol       Date:  2015-08-04       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.